Han, Hwa Seung Lee, Hansang You, DongGil Nguyen, Van Quy Song, Dae-Geun Oh, Byeong Hoon Shin, Sol Choi, Ji Suk Kim, Jae Dong Pan, Cheol-Ho Jo, Dong-Gyu Cho, Yong Woo Choi, Ki Young Park, Jae Hyung 2024-01-19T17:34:32Z 2024-01-19T17:34:32Z 2021-09-04 2020-04-10 0168-3659 https://pubs.kist.re.kr/handle/201004/118734 Liver fibrosis is an excessive wound healing process that occurs in response to liver damage depending on underlying aetiologies. Currently, there are no effective therapies and FDA-approved therapeutics for the treatment of liver fibrosis except liver transplantation. Multipotent adipose-derived stem cells (ADSCs) have received significant attention as regenerative medicine for liver fibrosis owing to their advantages over stem cells with other origins. However, intrinsic limitations of stem cell therapies, such as cellular rejection and tumor formation, have impeded clinical applications of the ADSC-based liver therapeutics. To overcome these problems, the extracellular nanovesicles (ENVs) responsible for the therapeutic effect of ADSCs (A-ENVs) have shown considerable promise as cell-free therapeutics for liver diseases. However, A-ENVs have not been used for the treatment of intractable chronic liver diseases including liver fibrosis and cirrhosis. Therefore, in this study, we investigated the in vitro and in vivo antifibrotic efficacy of A-ENVs in thioacetamide-induced liver fibrosis models. A-ENVs significantly downregulated the expression of fibrogenic markers, such as matrix metalloproteinase-2, collagen-1, and alpha-smooth muscle actin. The systemic administration of A-ENVs led to high accumulation in fibrotic liver tissue and the restoration of liver functionality in liver fibrosis models through a marked reduction in alpha-SMA and collagen deposition. These results demonstrate the significant potential of A-ENVs for use as extracellular nanovesicles-based therapeutics in the treatment of liver fibrosis and possibly other intractable chronic liver diseases. English ELSEVIER HEPATIC STELLATE CELLS TISSUE GROWTH-FACTOR BONE-MARROW CORD BLOOD IN-VITRO EXOSOMES MSC INJURY MOUSE THERAPIES Human adipose stem cell-derived extracellular nanovesicles for treatment of chronic liver fibrosis Article 10.1016/j.jconrel.2020.01.042 1 JOURNAL OF CONTROLLED RELEASE, v.320, pp.328 - 336 JOURNAL OF CONTROLLED RELEASE 320 328 336 scie scopus 000522794800027 2-s2.0-85078679403 Chemistry, Multidisciplinary Pharmacology & Pharmacy Chemistry Pharmacology & Pharmacy Article HEPATIC STELLATE CELLS TISSUE GROWTH-FACTOR BONE-MARROW CORD BLOOD IN-VITRO EXOSOMES MSC INJURY MOUSE THERAPIES Liver fibrosis Adipose-derived stem cells Extracellular nanovesicles